Immunology & Hematology & Internal Medicine & Family Medicine
Total IgM
Immunoglobulin M (IgM) antibodies are the antibodies of the primary immune response—the first to be produced upon initial contact with an antigen, before isotype switching to IgG, IgA, or IgE. They account for approximately 5–10% of total serum immunoglobulins, with normal values ranging from 0.40 to 2.30 g/L in adults, depending on the laboratory. Their structure is unique among immunoglobulins: serum IgM exists primarily as a pentamer (five subunits linked by a J chain), which confers very high antigenic avidity (ten antigen-binding sites per molecule) and highly effective complement activation (classical pathway). Surface IgM (mIgM) on naive B lymphocytes constitutes the B-cell antigen receptor (BCR) along with IgD, representing the first line of antigen recognition. In clinical practice, total IgM levels are measured as part of the evaluation of humoral immune deficiencies (comprehensive panel including IgG + IgA + IgM), hypogammaglobulinemias, and in the assessment of elevated total immunoglobulins or a monoclonal peak on protein electrophoresis. Infection-specific IgM antibodies (anti-HAV, anti-HBV, anti-HEV, anti-CMV, anti-EBV, anti-Toxoplasma, anti-parvovirus B19) are also the gold standard serological markers for detecting acute or recent infection, with their presence indicating primary infection or early reactivation. An isolated elevation in total IgM suggests Waldenström’s macroglobulinemia or other IgM-associated lymphoproliferative disorders.
Biology of IgM, Functions, and Reference Values
- Structure, biological functions, and kinetics of IgM: Pentameric structure of serum IgM: 5 monomeric subunits (each composed of 2 heavy µ chains + 2 light κ or λ chains) → linked by a J chain + disulfide bridges → 900 kDa pentamer → 10 antigen-binding sites (maximum avidity) → IgM generally has only low affinity for each individual epitope, but its high avidity compensates → advantage in the primary response (before affinity maturation) → surface IgM (mIgM): monomer (membrane IgM) → antigen receptor on naive B cells (in complex with Igα/Igβ — CD79a/b) → B-cell activation + signaling → serum half-life: 5–10 days (vs. IgG: 21–28 days) → low transplacental transfer: IgM does not cross the placenta (too large for FcRn or passive placental transport) → the presence of IgM in a newborn’s serum = sign of congenital infection (TORCH) + IgM is found primarily in the intravascular compartment (20–25% vs. IgG 40–45%) → primary immune response and kinetics: First exposure to an antigen → activation of naive B lymphocytes → clonal expansion → IgM production (peak at days 7–14 → decline begins at days 21–28) → isotype switching (IgM → IgG + IgA) under the influence of IL-4 + CD40L → IgG production on days 14–21 → immune memory → upon re-exposure (secondary response): IgG produced more rapidly and in greater quantities → lower secondary IgM levels and earlier peaks → specific IgM therefore serve as markers of recent acute infection (peak during the acute phase); biological functions of IgM: effective complement activation (classical pathway): pentameric IgM binds to C1q → activation of C1 → C4 + C2 → C3 convertase → C3a + C3b (opsonization) + C5a (chemotaxis) + C5b–9 (membrane attack complex — bacterial lysis) → IgM are the most effective activators of the complement via the classical pathway → agglutination: the 10 binding sites allow for effective agglutination of pathogens + red blood cells → Coombs test (anti-red blood cell antibodies) → cold-reactive IgM (IgM cryoglobulins + cold antibodies) → opsonization → recognition of pathogens by FcµR (IgM Fc receptors) on macrophages + NK cells → role in defense against encapsulated bacteria (pneumococcus ++) before IgG memory is established; Normal IgM levels by age: newborn: 0–0.04 g/L (maternal IgM does not cross the placenta → detectable IgM in a newborn = congenital infection) → 2–6 months: 0.18–0.88 g/L → 1–3 years: 0.43–1.96 g/L → 4–12 years: 0.50–1.70 g/L → adults: 0.40–2.30 g/L → slight downward trend after age 70 + IgM levels rise physiologically during acute infections (primary response) before declining
- IgM deficiencies — selective IgM deficiency and hypogammaglobulinemias: Selective IgM deficiency (sIgMD): IgM <0.40 g/L + normal IgG and IgA → second most common primary immunodeficiency (after IgA deficiency) → prevalence: 0.03–0.08% of the general population → complex, poorly understood genetics → 75–80% of individuals with IgM-deficient primary immunodeficiency are asymptomatic → clinical manifestations if symptomatic: recurrent bacterial infections (especially infections with encapsulated bacteria—pneumococcus + H. influenzae—particularly in the absence of vaccination + Giardia) → mechanism: reduced complement activation via IgM → reduced early opsonization → autoimmune diseases (30–40% of symptomatic IgM-deficient individuals): LES + idiopathic thrombocytopenic purpura + autoimmune hemolytic anemia + atopic diseases (paradoxical increase in allergies) → Gupta 1994 — Annals of Allergy: DSIgM + recurrent infections + autoimmune diseases → variable clinical relevance → Wiśniewski 2019 — Frontiers in Immunology: review of DSIgM → clinical manifestations + management → no established specific treatment → antibiotic prophylaxis if recurrent infections + pneumococcal + meningococcal + H. influenzae type b vaccinations → no indication for IVIG in isolated DSIgM (normal IgG); Low IgM in systemic disorders: VCDI (Variable Common Deficiency): IgG + IgA + IgM all low → poorer prognosis if IgM <0.10 g/L → XLA (Bruton's agammaglobulinemia): quasi-absent IgM + IgG + quasi-absent IgA + absent B lymphocytes → prolonged corticosteroid therapy + immunosuppressive agents → lymphomas + leukemias treated by chemotherapy → splenectomy (reduction in splenic IgM production) → baseline IgM is lower in splenectomized patients → increased susceptibility to pneumococci + meningococci (OPSI - overwhelming post-splenectomy infection)
Elevated IgM, specific IgM, and management
| Situation / pathology | Data, criteria and procedures | Key studies and recommendations |
|---|---|---|
| Elevated IgM — diagnostic orientation and Waldenstrom macroglobulinemia Monoclonal IgM — Macroglobulinemia — Hyperviscosity — Electrophoresis — Immunofixation — Lymphoplasmacytes — MYD88 — Rituximab — Ibrutinib — Polyclonal — Infections — Autoimmunity |
Diagnostic approach for elevated IgM levels (>2.30 g/L): Step 1 — serum protein electrophoresis (SPE): monoclonal peak in the β or γ band → immunofixation (IFX) → confirms monoclonal IgM + light chain type (κ or λ) → polyclonal IgM → diffuse elevation in the γ band → no narrow peak; Causes of elevated polyclonal IgM: recent or chronic infections (primary immune response) → HAV + HBV + HEV (acute phase) + EBV (primary infection) + CMV + parvovirus B19 + rubella + toxoplasmosis + Trypanosoma brucei (African trypanosomiasis — very high IgM levels) + bacterial endocarditis → chronic inflammatory conditions: autoimmune diseases (SLE + Sjögren’s syndrome + RA) + liver cirrhosis (polyclonal stimulation by bacterial antigens) + sarcoidosis + type II cryoglobulins (IgM + IgG) → main cause of mildly elevated polyclonal IgM + rheumatoid factor (RF): IgM-anti-IgG complexes → RF = IgM in 70–80% of RF-positive cases → measured separately (nepheloimetry or ELISA) → diagnostic value in RA (75–80% of RA cases) + Still’s disease + endocarditis + certain infections; Waldenström’s macroglobulinemia (WM) — monoclonal IgM: definition: lymphoplasmacytic lymphoma (LPL) producing monoclonal IgM → characterized by bone marrow infiltration + sometimes lymph node and splenic infiltration by lymphoplasmocytes → monoclonal IgM often >10–30 g/L → prevalence: 1–2/100,000 + median age at diagnosis: 65 years → genetic marker: MYD88 L265P mutation (90% of LPL cases) + detected by PCR or sequencing + Treon 2012 — NEJM: MYD88 mutation + WM → diagnostic marker + therapeutic target + clinical manifestations: hyperviscosity syndrome: pentameric IgM → massive increase in serum viscosity → Meltzer 1962 — American Journal of Medicine: serum viscosity >4 cP → symptoms of hyperviscosity: headaches + dizziness + visual disturbances (dilated retinal vessels + retinal hemorrhages) + neurological disturbances (confusion + drowsiness) + mucosal bleeding → indication for urgent plasmapheresis if viscosity >4–5 cP + symptoms + other manifestations: anemia (bone marrow infiltration + hemodilution) + peripheral neuropathy (anti-MAG antibodies — anti-myelin-associated glycoprotein) + cryoglobulinemia + renal IgM deposits + amyloidosis → diagnosis of WM: EPS + IFX → monoclonal IgM + bone marrow biopsy (confirms lymphoplasmacytic infiltration ≥10% + immunophenotype: CD19+ + CD20+ + CD22+ + low CD138 + surface IgM) + MYD88 mutation + WM treatment: observation if asymptomatic (smoldering WM) → treatment if: symptoms + hyperviscosity + cytopenias + neuropathy + rituximab (anti-CD20) + bendamustine: R-Benda regimen → or rituximab + cyclophosphamide + dexamethasone (RCD) + ibrutinib (Zydelig / Imbruvica): BTK inhibitor → highly effective in WM (even as monotherapy) + Treon 2015 — NEJM: ibrutinib + refractory WM → response rate 91% % → zanubrutinib (Brukinsa): second-generation BTK inhibitor → Dimopoulos 2023 — NEJM: zanubrutinib superior to ibrutinib in WM → fewer cardiovascular effects + biological monitoring: monoclonal IgM before each treatment cycle + CBC + serum viscosity if IgM >30 g/L; IgM MGUS: monoclonal IgM <30 g/L + bone marrow infiltration <10% % + no symptoms (no CRAB) + risk of progression to WM or lymphoma: 1.5% %/year + Kyle 2003 — Blood: IgM MGUS → risk of progression → EPS monitoring + IFX annually + CBC | Treon 2012 — NEJM: MYD88 L265P mutation + WM → diagnostic marker + therapeutic target + Treon 2015 — NEJM: ibrutinib + refractory WM → response rate 91% (%) → landmark publication on ibrutinib in WM + Dimopoulos 2023 — NEJM: zanubrutinib superior to ibrutinib in WM → ASPEN trial + Kyle 2003 — Blood: IgM MGUS → risk of progression 1.5 %/year → surveillance + Meltzer 1962 — American Journal of Medicine: hyperviscosity syndrome + WM → thresholds + symptoms + Swerdlow 2016 — Blood (WHO Classification 5th edition): LPL + WM → diagnostic criteria + IWWM (International Workshop on Waldenström Macroglobulinemia) 2022: updated guidelines for the diagnosis + treatment of WM + NCCN 2023: recommendations for WM + ibrutinib + zanubrutinib + Health Canada: approvals for ibrutinib (Imbruvica) + zanubrutinib (Brukinsa) in WM |
| Specific IgM — markers of acute infection and IgM autoantibodies IgM anti-HAV — IgM anti-HBc — IgM anti-HEV — IgM anti-CMV — IgM anti-EBV — IgM anti-toxoplasma — IgM anti-parvovirus — IgM rheumatoid factor — cryoglobulins — cold agglutinins — TORCH |
Specific IgM as markers of acute infection: general interpretation: positive specific IgM → recent acute infection (primary infection) or early reactivation → IgM generally persists for 3–6 months (depending on the agent) → positive specific IgG + negative IgM → past infection + acquired immunity; main serological tests using IgM: hepatitis A (HAV): anti-HAV IgM: positive from the onset of symptoms (days 7–10) → persist for 4–6 months → confirm acute primary infection → anti-HAV IgG: vaccine-induced or post-infection immunity → hepatitis B (HBV): anti-HBc IgM (anti-core antibodies): marker of acute hepatitis B → positive in the first weeks of acute hepatitis B → disappear upon recovery → but: may persist at low titers in chronic hepatitis B → if anti-HBc IgM is elevated → hepatitis B flare-up (acute or exacerbation of chronic hepatitis) → anti-HBc IgG: past infection or chronic hepatitis + hepatitis E (HEV): anti-HEV IgM: marker of recent primary infection → pregnancy + immunocompromised individuals → high risk of fulminant hepatitis → EBV (Epstein-Barr): Anti-VCA (Viral Capsid Antigen) IgM: acute primary infection (infectious mononucleosis) → positive at symptom onset → persists for 4–8 weeks → anti-VCA IgG + anti-EBNA IgG negative at onset → EBNA seroconversion at 3–6 months → CMV (Cytomegalovirus): Anti-CMV IgM: primary infection + may persist for several months → risk of reactivation during pregnancy → Anti-CMV IgG: past infection + ≥50% of the Canadian adult population is IgG+ → toxoplasmosis: Anti-Toxoplasma IgM: recent primary infection → sometimes persists >12 months (note: late-stage positive IgM does not indicate recent infection) → anti-Toxoplasma IgG: past immunity → IgG avidity test: high avidity (>0.3 index) → infection >4 months → rules out recent infection in pregnant women → Parvovirus B19: Anti-Parvovirus B19 IgM: infectious erythema + erythroblastic aplasia + fetal anasarca → positive at onset of symptoms → persists 2–3 months → Rubella: anti-rubella IgM: primary infection (serious consequences in pregnancy — congenital rubella syndrome) → positive on days 4–8 after the onset of the rash → persists for 4–8 weeks → Quebec vaccination program (MMR): rubella IgG screening before pregnancy → herpes simplex (HSV): Anti-HSV IgM: nonspecific markers (repeated reactivations + frequent false positives) → prefer PCR for diagnosis; IgM-type autoantibodies: IgM-type rheumatoid factor (RF): IgM directed against the Fc fragment of IgG → positive titer if >14–20 IU/mL depending on the laboratory → associated with RA + but also: Sjögren’s syndrome + SLE + HCV + infective endocarditis + cryoglobulinemia + certain infections + sensitivity in RA: 75–80% sensitivity → limited specificity → IgM RF alone is not sufficient for RA diagnosis → always combine with anti-CCP (anti-citrullinated proteins), which is more specific (95% sensitivity) → cold agglutinins: Cold IgM → binds to erythrocyte antigens at low temperatures (0–4°C) → cold agglutinin hemolytic anemia (cold AIHA) → post-infectious (Mycoplasma pneumoniae + EBV) → or cold agglutinin disease (chronic — monoclonal anti-I/i IgM) → significant titers if >64 in the standard test + symptoms: acrocyanosis + livedo in the cold + hemoglobinuria → treatment: rituximab (first-line) + avoidance of cold → type I cryoglobulinemia (monoclonal IgM): precipitation at low temperatures → purpura + neuropathy + glomerulonephritis + treatment of the underlying monoclonal IgM | WHO + CDC: IgM serology for the diagnosis of acute infections → standardized interpretations → Lappalainen 1993 — Journal of Clinical Microbiology: anti-Toxoplasma IgG avidity → high avidity excludes recent primary infection + Huzly 2018 — Journal of Clinical Virology: anti-rubella IgM + diagnosis of acute rubella → Busch 2000 — Transfusion: anti-CMV IgM + blood donors → serology + PCR + Nimmerjahn 2008 — Nature Reviews Immunology: structure and functions of IgM + FcµR + Bäumer 2023 — Frontiers in Immunology: FcµR + IgM + biological roles + Gupta 1994 — Annals of Allergy: DSIgM + recurrent infections + AAAAI/ACAAI: IgM rheumatoid factor in RA + diagnosis + Deane 2010 — Nature Reviews Rheumatology: IgM RF + anti-CCP + RA → combined diagnosis → SDDI INSPQ Quebec: serological protocols for infectious diseases + Quebec Prenatal Serology Program (PQSP): rubella + toxoplasmosis + IgM screening + Quebec MSSS Hepatitis B/A/E Serology Guide |
| Management of Abnormal IgM and Special Situations Splenectomy - post-splenectomy prophylaxis - OPSI - elevated newborn IgM - TORCH - pregnancy - cryoglobulinemia - rituximab - cold agglutinin disease - IgM in IBD |
Splenectomy and low IgM levels — increased risk of infection: the spleen is the primary organ responsible for producing "natural" IgM " (non-immunized IgM — natural repertoire IgM) → primary response to encapsulated bacteria (pneumococcus + H. influenzae + meningococcus) → post-splenectomy → reduction in IgM + reduction in splenic antibody production → risk of OPSI (Overwhelming Post-Splenectomy Infection): fulminant sepsis caused by encapsulated bacteria → mortality 40–70% within 1–3 years without early treatment → incidence: 3–5% lifetime risk + highest risk in the first 2 years post-splenectomy → but persists for life → prophylaxis and prevention of OPSI: vaccinations before splenectomy (ideally 2 weeks prior): pneumococcal vaccine (Pneumovax 23 + Prevnar 20 if not previously vaccinated) + meningococcal vaccine (Men ACYW + MenB) + Haemophilus influenzae type b vaccine (if not previously immunized) + hepatitis A + hepatitis B + annual influenza vaccine → post-splenectomy antibiotic prophylaxis: oral penicillin V 250–500 mg × 2/day → or amoxicillin 250 mg/day → for at least 2 years after splenectomy (some recommend lifelong) → or macrolides if allergic + Haematological Society of Australia and New Zealand (HSANZ) 2019: post-splenectomy guidelines → vaccinations + prophylaxis → Welsh Asplenia Working Party 2022 (UK) + Rubin 2014 — NEJM: vaccination + post-splenectomy prophylaxis → significant reduction in the risk of OPSI → medical record noting splenectomy → standby antibiotics at home (amoxicillin-clavulanate) → seek emergency care at the first sign of fever + elevated IgM in the newborn — congenital infections (TORCH): maternal IgM does not cross the placenta → any IgM >0.02 g/L in the newborn = endogenous (neonatal) production → sign of congenital infection → TORCH panel: Toxoplasma + Others (HAV + HBV + HEV + syphilis + varicella-zoster) + Rubella + CMV + Herpes simplex + enterovirus → positive anti-TORCH IgM → confirms congenital infection + targeted etiological workup → specific IgM (anti-CMV IgM + anti-toxoplasma IgM + anti-rubella IgM) confirm the agent → PCR if necessary; cryoglobulinemia and cold agglutinin disease: type I cryoglobulinemia (pure monoclonal IgM): precipitates at 4°C + redissolves at 37°C → cold-induced clinical manifestations: vascular purpura + livedo + Raynaud’s phenomenon + ischemic ulcers + neuropathy + glomerulonephritis → treatment of underlying WM + type II cryoglobulinemia (IgM + IgG — mixed): monoclonal anti-IgG IgM + polyclonal IgG → associated with hepatitis C in 80% of cases + SLE + Sjögren’s syndrome → treatment of HCV (direct-acting antivirals — DAAs) → rituximab + cold agglutinin disease (CAD): Cold anti-I or anti-i IgM → chronic hemolytic anemia + acrocyanosis + rituximab ± bendamustine (R-Benda) → suvorexant → not here → sutimlimab (Enjaymo): C1s inhibitor (classical complement pathway) → approved by the FDA in 2022 + Health Canada in 2022 for CAD → Röth 2021 — NEJM (CADENZA trial): sutimlimab → cessation of hemolysis + improvement in anemia → no transfusions in 54% of patients + iptacopan (factor B) → in trials for FMA; IgM in IBD (Crohn’s disease + UC): chronic stimulation of intestinal MALT → IgM often slightly elevated (polyclonal) → no specific clinical significance beyond the normally elevated IgM levels seen in chronic inflammatory conditions | Röth 2021 — NEJM (CADENZA trial): sutimlimab + MAF → cessation of hemolysis + improvement in anemia → FDA approval 2022 + Health Canada 2022 + HSANZ 2019: post-splenectomy guidelines → vaccinations + prophylaxis → Welsh Asplenia Working Party 2022 + Rubin 2014 — NEJM: vaccination + post-splenectomy prophylaxis → reduction of OPSI + Treon 2012 — NEJM + Dimopoulos 2023 — NEJM: WM + MYD88 + zanubrutinib → Wiśniewski 2019 — Frontiers in Immunology: DSIgM → review + clinical manifestations + Nimmerjahn 2008 — NRI: IgM + biological functions + Lappalainen 1993 — JCM: toxoplasmosis + avidity test → INSPQ SDDI + Quebec Prenatal Serology Program (PQSP) + Rubin 2014 — NEJM: post-splenectomy + vaccinations + prophylaxis → Health Canada: sutimlimab (Enjaymo) + ibrutinib + zanubrutinib approved in Canada + Immunodeficiency Canada + CAAIF: resources for immunodeficiencies including DSIgM |
ℹ️
The presence of detectable IgM in a newborn is always abnormal — maternal IgM does not cross the placenta, therefore any IgM positive at birth signifies a congenital infection: A TORCH panel (Toxoplasmosis, Rubella, CMV, Herpes, and others) should be initiated. Furthermore, a monoclonal IgM found on protein electrophoresis should prompt investigation for Waldenström's macroglobulinemia (bone marrow biopsy + MYD88 mutation) or IgM MGUS. Post-splenectomy patients have naturally low IgM levels and should be vaccinated and receive antibiotic prophylaxis to prevent infections from encapsulated bacteria.
Situations requiring urgent care
Known patient with Waldenström's macroglobulinemia or very high monoclonal IgM (>40 g/L) presenting with headaches + visual disturbances + dizziness + confusion + mucosal bleeding → Hyperviscosity syndrome → Medical emergencies → Serum viscosity measurement → If >4 cP + symptoms → Emergency plasmapheresis/plasma exchange → Rapid reduction of IgM level + underlying treatment for WM → Ibrutinib + rituximab depending on patient's condition.
Newborn with total IgM > 0.02 g/L detected on neonatal blood screening or in the presence of clinical signs (microcephaly + chorioretinitis + hepatosplenomegaly + purpura + congenital cataracts) → congenital infection (TORCH) → specific IgM testing (anti-CMV + anti-toxoplasmosis + anti-rubella + anti-HSV) + PCR blood + CSF according to clinical presentation → urgent pediatric consultation → treatment if congenital CMV or toxoplasmosis confirmed.
Patient with recent splenectomy (<2 years) presenting with fever ≥39°C + chills + rapid deterioration of general condition without an obvious infectious focus → OPSI (Overwhelming Post-Splenectomy Infection) until proven otherwise → medical emergencies → blood cultures × 3 + immediate IV antibiotics (amoxicillin-clavulanate IV +/- ceftriaxone) → without antibiotics → possible death within hours → check vaccination status → inform nursing staff of splenectomy.
Chronic hemolytic anemia + acrocyanosis + cold-induced Raynaud's phenomenon + strongly positive cold agglutinins (>64) in a middle-aged to elderly adult → Cold agglutinin disease (CAD) → etiological workup (EPS + IFX + monoclonal vs. polyclonal IgM + CMV serology + mycoplasma) → hematologist consultation → rituximab ± bendamustine → sutlimab if severe refractory anemia.
Consult at Clinique Omicron
Clinique Omicron physicians prescribe and interpret total IgM levels as part of a complete immunological assessment, for acute infection serology, for the evaluation of monoclonal gammopathy, and for post-splenectomy follow-up. They refer patients to hematology for elevated monoclonal IgM, ensure post-splenectomy prophylaxis (vaccinations + antibiotics), and manage specific IgM in the diagnosis of acute infections. Consultations are available at several service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is provided for informational purposes only and does not substitute for the advice of a physician, immunologist, or hematologist. Monoclonal IgM or hyperviscosity should always be evaluated by a specialist.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.